1. Delayed subsequent denosumab doses were shown to increase the risk for vertebral fractures compared to on-time injection.
2. There was insufficient evidence to determine if with delayed dosing, fracture risk at other locations would be increased.
Evidence Rating Level: 2 (Good)
Study Rundown: Denosumab, a monoclonal antibody that inhibits the RANK...